多剤耐性結核の治療成績 : 菌陰性化成功例と失敗例の比較から TREATMENT OUTCOMES OF MULTIDRUG-RESISTANT TUBERCULOSIS : Comparison between Success and Failure Cases

この論文にアクセスする

この論文をさがす

著者

抄録

The thirty-two times of treatment in 27 patients with multidrug-resistant tuberculosis (MDR?TB) were analyzed retrospectively. In twenty-eight times of treatments cases had previous histories of antituberculosis chemotherapy. Drug sensitivity tests were performed by Microtiter method for isoniazid (INH), rifampicin (RFP), ethambutol, streptomycin, kanamycin, enviomycin, ethionamide, para-aminosalicylic acid and cycloserine. A drug is defined as 'active drug' when the drug was proved to be sensitive by the drug sensitivity tests or never used in the past or used for not more than 2 months in case of pyrazinamide (PZA) and less than one month for fluoroquinolones. Outcomes of treatments were grouped as follows; A: bacteriologically negative for more than 24 months, B: bacteriologically negative for more than 6 months but less than 24 mont hs, C: bacteriologically relapsed after negative conversion, D: continuously bacilli positive for <I>M. tuberculosis.</I> Mean age of patients in each group were; 61.0 yrs for group A (n=10), 61.0 yrs for group B (n=7), 52.5 yrs for group C (n=4), 57.9 yrs for group D (n=11). All patients had cavitary disease and positive sputum smears for acid-fast bacilli. Mean numbers of 'active drugs' used per treatment in each group, were 3.6, 3.3, 2.5 and 1.8respectively, while the mean number of resistant drug including INH and RFP were 2.8, 3.3, 2.5 and 3.7. The number of drugs, which was unable to use due to toxicity, were 0.20, 0.14, 0.50, and 0.73 per treatment respectively. All of 9 patients treated with four 'active drugs' were in group A or B and succeeded to achieve negative conversion. The duration of chemotherapy in group A was 13 to 44 months. Treatment had failed in 4out of 11 patients treated with 3 'active drugs' and 11 out of 12 patients treated with less than 2 'active drugs' Fluoroquinolones (ofloxacin, levofloxacin or sparfloxacin) were used in 7 out of 10 patients in group A and in 6 out of 9 patients treated with four-drug regimens while they were used only in 3 out of 11 patients in group D. Regimens with at least 4 sensitive drugs are mandatory for the successful treatment of MDR-TB and fluoroquinolones are needed in the majority of cases to ensure the four-drug regime n, because of frequent drug resistance or toxicity to other antituberculosis drugs.

収録刊行物

  • 結核

    結核 76(12), 723-728, 2001-12-15

    JAPANESE SOCIETY FOR TUBERCULOSIS

参考文献:  11件中 1-11件 を表示

被引用文献:  5件中 1-5件 を表示

各種コード

  • NII論文ID(NAID)
    10008113112
  • NII書誌ID(NCID)
    AN00073442
  • 本文言語コード
    JPN
  • 資料種別
    ART
  • ISSN
    00229776
  • NDL 記事登録ID
    026781062
  • NDL 請求記号
    Z19-133
  • データ提供元
    CJP書誌  CJP引用  NDL  J-STAGE 
ページトップへ